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Abstract
Background: Despite advances in supportive care, moderate-severe acute respiratory distress syndrome (ARDS) is
associated with high mortality rates, and novel therapies to treat this condition are needed. Compelling pre-clinical
data from mouse, rat, sheep and ex vivo perfused human lung models support the use of human mesenchymal
stem (stromal) cells (MSCs) as a novel intravenous therapy for the early treatment of ARDS.
Methods: This article describes the study design and challenges encountered during the implementation and
phase 1 component of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of bone marrow-derived
human MSCs for moderate-severe ARDS. A trial enrolling 69 subjects is planned (9 subjects in phase 1, 60 subjects
in phase 2 treated with MSCs or placebo in a 2:1 ratio).
Results: This report describes study design features that are unique to a phase 1 trial in critically ill subjects and the
specific challenges of implementation of a cell-based therapy trial in the ICU.
Conclusions: Experience gained during the design and implementation of the START study will be useful to
investigators planning future phase 1 clinical trials based in the ICU, as well as trials of cell-based therapy for other
acute illnesses.
Trial registration: Clinical Trials Registration: NCT01775774 and NCT02097641.
Keywords: Acute lung injury; Clinical trial; Mesenchymal stem/stromal cell; Pulmonary edema
Background
Morbidity and mortality have declined only modestly in
patients with the acute respiratory distress syndrome
(ARDS) in the last decade despite extensive research into
its pathophysiology [1-3]. Current treatment remains
primarily supportive with lung-protective ventilation and
a fluid conservative strategy [4,5]. Pharmacologic therapies
that reduce the severity of lung injury in vivo and in vitro
have not yet been translated to effective clinical treatment
options. At present, the mortality rate of severe ARDS re-
mains unacceptably high, in the range of 30 to 40% [6,7].
Therefore, innovative therapies are needed, in particular
for individuals with moderate-severe ARDS who have the
highest mortality rates.
Cell-based therapy with human mesenchymal stem/
stromal cells (MSCs) is attractive as a potential new
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the ability to secrete multiple paracrine factors, such as
growth factors that can enhance tissue repair, anti-inflam-
matory cytokines that can reduce inflammation, and anti-
microbial peptides that can reduce the severity of bacterial
infection [8-17]. MSCs can also transfer mitochondria to
injured lung epithelial cells, thus enhancing their func-
tional status by replenishing depleted levels of ATP [18].
All of these mechanisms are relevant to the major abnor-
malities that underlie ARDS, including impaired alveolar
fluid clearance, altered lung endothelial and epithelial per-
meability, dysregulated inflammation and ongoing infec-
tion. To date, MSCs have been tested for a variety of
indications in more than 2,000 human subjects as therapy
for a variety of diseases due to their low immunogenicity,
immunomodulatory effects, and ability to secrete endo-
thelial and epithelial growth factors.
Pre-clinical studies in small and large animal models
(mouse, rat, and sheep), as well as in an ex vivo perfused
human lung model, have demonstrated the potential
efficacy and safety of administering human MSCs for
the treatment of ARDS [8,9,11,12,14]. Based on these
studies, we proposed a phase 1 dose escalation trial
followed by a phase 2 randomized, double-blind, placebo-
controlled clinical trial of human MSCs for the treatment
of moderate-severe ARDS. The purpose of this article is to
describe the design of this clinical trial and the particular
challenges we faced in testing a cell-based therapy in a
critically ill population of patients with moderate-severe
ARDS. We also present practical lessons learned during
the implementation of the phase 1 trial relevant to both
future trials of cell-based therapies and to other phase 1
trials in critically ill patients.
Methods
Study overview
The START trial is a multicenter phase 1/phase 2 clinical
trial of MSCs in patients with moderate-severe ARDS, de-
fined as a PaO2/FiO2 ratio of less than 200 mmHg while
on positive pressure ventilation with at least 8 cmH2O
positive end-expiratory pressure (PEEP) [19].
The phase 1 component of the study is an open label
dose escalation pilot study in which three cohorts of
subjects with ARDS receive increasing doses of human
MSCs administered as a single intravenous infusion.
There are three subjects per cohort, with patients in
each cohort receiving either 1× 10
6 cells/kg predicted body
weight (first cohort), 5× 10
6 cells/kg predicted body weight
(second cohort), or 10×10
6 cells/kg predicted body weight
(third cohort).
Phase 2 is a randomized, double-blind placebo-con-
trolled study using the maximally tolerated dose (MTD)
of cells from the phase 1 study (up to 10×10
6 cell/kg pre-
dicted body weight). The MTD is the highest dose that is
associated with no pre-specified infusion associated events
or unexpected severe adverse attributed to the study prod-
uct. Subjects will be randomized in a 2:1 randomization
scheme to receive human MSCs or Plasma-lyte A placebo;
the study will enroll 60 patients who achieve a stable
clinical baseline and receive the investigational product.
The coordinating center for the trial is at the University of
California, San Francisco. Eligible study subjects will be
enrolled in the phase 1 trial at the University of California,
San Francisco, Stanford University, and the Massachusetts
General Hospital. Planned phase 2 sites also include the
University of Pittsburgh and the University of Vermont.
The trial is funded by the National Institutes of Health
through a Clinical and Translational Science Institute
award to the University of California, San Francisco and
through the National Heart, Lung and Blood Institute
(NHLBI) Pilot Trials in Lung Disease U01 mechanism and
the NHLBI-supported Production Assistance for Cellular
Therapies (PACT) program at the University of Minnesota.
The human MSCs are prepared from donor bone marrow
at the University of Minnesota and shipped frozen to
the clinical sites. Prior to administration, cells are thawed,
washed and reconstituted at the clinical site, as detailed
below.
Study endpoints
Primary endpoints: safety
Because this is a first-in-humans application of human
MSCs in patients with moderate-severe ARDS, the pri-
mary study endpoints for both phase 1 and phase 2 will
focus on the safety and tolerability of the human MSCs
product. In phase 1, this analysis will examine (1) the
incidence of pre-specified infusion associated events and
(2) unexpected severe adverse events in ARDS patients
treated with human MSCs. For phase 2, the MTD will
be used, and the primary endpoint will be (1) the inci-
dence of pre-specified infusion associated events and (2)
the rate of unexpected severe adverse events observed in
ARDS patients treated with human MSCs compared to
patients treated with placebo.
Because infusion of MSCs could theoretically cause
transient obstruction of the pulmonary microcirculation
leading to (1) a fall in systemic blood pressure, (2) an in-
crease in vasopressor dose, (3) an increase in heart rate,
(4) an increase in arterial carbon dioxide concentration,
or a (5) a decline in oxygenation, patients will be moni-
tored closely by a study physician during the infusion
and for six full hours following the start of the infusion
for changes in any of these parameters. Pre-specified
infusion associated events will be defined as one of the
following events that occurs within six hours of the MSCs
infusion: an increase in vasopressor dose greater than
or equal to a predefined threshold, new ventricular
tachycardia, ventricular fibrillation or asystole, new cardiac
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an increase in the fraction of inspired oxygen of 0.2 or
more and an increase in the level of PEEP of 5 cmH20o r
more to maintain transcutaneous oxygen saturations in the
target range of 88 to 95%, or a clinical scenario consistent
with transfusion incompatibility or transfusion-related in-
fection. A two-hour stability period will be required prior
to MSC infusion. In addition, cardiac arrest/death within
24 hours of infusion would be considered a pre-specified
infusion associated event, since patients who are moribund
and not expected to survive 24 hours will be excluded from
the trial (Table 1).
The predefined threshold for increased vasopressor dos-
ing qualifying as a pre-specified infusion-associated adverse
event are described as in Table 1: an increase of more than
10 mcg/minute norepinephrine, 100 mcg/minute phenyl-
ephrine, 10 mcg/kg/minute dopamine, 0.1 mcg/kg/minute
of epinephrine or addition of a third vasopressor. These
predefined thresholds were determined based on what
investigators would consider significant increases in
vasopressor dosing.
In addition to these pre-specified infusion associated
adverse events, we will also systemically collect and review
the incidence and nature of all serious adverse events for
the duration of the clinical trial, with special attention to
adverse events that are unexpected in the clinical course
of a critically ill patient with ARDS.
Secondary endpoints: potential indicators of treatment
efficacy
Given the proposed paracrine effects of human MSCs,
we will test three categories of efficacy endpoints in the
phase 2 trial: respiratory, systemic and biologic. Respira-
tory efficacy endpoints will include the Lung Injury
Score (LIS) at day 3, since improvement in the LIS has
been shown to be associated with other clinical outcomes
[5,20,21], including an increased number of ventilator free
days and improved survival. The LIS is a composite scor-
ing system including the PaO2/FiO2, the level of positive
end-expiratory pressure, the extent of infiltrates on the
chest radiograph, and static respiratory compliance. The
other respiratory efficacy endpoints will include the PaO2/
FiO2 ratio and oxygenation index (OI) at day 3, which
incorporates mean airway pressure and the PaO2/FiO2.O I
is independently predictive of mortality in patients with
ARDS [22,23].
Systemic efficacy endpoints will include the mean
Sequential Organ Failure Assessment (SOFA) score [24] at
day 3 as well as ventilator-free [25], ICU-free, vasopressor-
free, and organ failure free days and 60 day all-cause mor-
tality, noting that this initial phase 2 clinical trial of
60 patients will be underpowered for these endpoints.
Biological endpoints will focus on the proposed mech-
anisms of action of the human MSCs in ARDS based on
preclinical studies. Specifically, we will measure plasma
markers of lung epithelial injury (Receptor for Advanced
Glycation Endproducts (RAGE)), pro- and anti-inflam-
matory markers (IL-6, IL-8, IL-10 and IL-1Ra), markers
of endothelial injury (von Willebrand factor, angiopoei-
tin-2), markers of other organ injury (creatinine) and
biomarkers that may reflect the paracrine activity of the
administered human MSCs (angiopoeitin-1 and kerati-
nocyte growth factor). All of these biomarkers will be
measured at baseline and day 3 using enzyme-linked
Table 1 Pre-specified infusion associated adverse events for START
Within six hours of the MSCs infusion Within 24 hours of the MSCs infusion
b
1. An increase in vasopressor dose greater than or equal to a predefined threshold: 1. Cardiac arrest
> 10 mcg/minute norepinephrine 2. Death
> 100 mcg/minute phenylephrine
> 10 mcg/kg/minute dopamine
> 0.1 mcg/kg/minute of epinephrine
a
Addition of a third vasopressor
2. New ventricular tachycardia, ventricular fibrillation or asystole
3. New cardiac arrhythmia requiring cardioversion
4. Hypoxemia requiring an increase in the fraction of inspired oxygen of 0.2 or
more and an increase in the level of PEEP of 5 cmH20 or more to maintain
transcutaneous oxygen saturations in the target range of 88 to 95%
5. A clinical scenario consistent with transfusion incompatibility or transfusion-related
infection (urticaria, wheezing)
aAlthough patients on epinephrine were excluded from the original clinical trial protocol, because of the current Surviving Sepsis Guidelines and the use of
epinephrine as a first line vasopressor in at least one study hospital ICU, the protocol was amended to allow patients on a modest dose of epinephrine to be
included in the trial and to define a pre-specified infusion associated event based on epinephrine dosing.
bSince patients who are moribund and not expected to survive 24 hours are excluded from the study.
Liu et al. Annals of Intensive Care 2014, 4:22 Page 3 of 9
http://www.annalsofintensivecare.com/content/4/1/22immunoassays (ELISAs). In the phase 2 study, we
plan to measure a marker of lung epithelial perme-
ability (total protein concentration in a mini-
bronchoalveolar lavage obtained 48 hours after prod-
uct infusion using a colorimetric assay) [26] as well
as the total and differential cell count in the mini-
bronchoalveolar lavage specimen.
Selection of study subjects
The inclusion and exclusion criteria (Table 2) are
intended to identify a group of patients with sufficiently
high mortality to benefit from MSC therapy, but also to
exclude patients at higher risk of complications since
this is a phase 1/2 trial. The inclusion criterion for study
entry is the presence of moderate-severe ARDS, defined
as the acute onset of the need for positive pressure
ventilation by an endotracheal or tracheal tube with a
PaO2/FiO2 ratio <200 with at least 8 cmH2O positive
end-expiratory airway pressure (PEEP), bilateral infil-
trates consistent with pulmonary edema on frontal chest
radiograph and no clinical evidence of left atrial
hypertension for the bilateral pulmonary infiltrates.
To avoid enrolling patients with late ARDS, patients
must be enrolled and randomized within 96 hours of
meeting the Berlin definition for ARDS (Table 2, ex-
clusion 2). At the time of randomization, all inclusion
criteria must be met. Subjects must receive the study
infusion (either MSCs in phase 1 or MSCs/placebo in
phase 2) within 120 hours of meeting the Berlin def-
inition for ARDS. During this period, the PaO2/FiO2
ratio must remain < 300 mmHg on a PEEP of at least
8c m H 2O.
Another unique design feature of this trial is that
we have mandated that enrolled patients achieve a
two-hour stable baseline period prior to administra-
tion of MSCs. The stable baseline criteria are as
follows:
Baseline stability criteria that must be met prior to hu-
man mesenchymal stem cell (MSC) infusion
In the supine position, patients must sustain:
Table 2 Inclusion and exclusion criteria for START
Inclusion criteria Exclusion criteria
Patients will be eligible for inclusion if they meet all of the below
criteria. Criteria 1 to 3 must all be present within a 24-hour time
period and at the time of enrollment:
1. Age younger than 18 years
1. A need for positive pressure ventilation by an endotracheal or
tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cmH2O
positive end-expiratory airway pressure (PEEP)
2. Greater than 96 hours since first meeting ARDS criteria
per the Berlin definition [19]
2. Bilateral infiltrates consistent with pulmonary edema on frontal
chest radiograph, and
3. Pregnant or breast-feeding
No clinical evidence of left atrial hypertension, or if measured, a
Pulmonary Arterial Occlusion Pressure (PAOP) less than or equal
to 18 mmHg
4. Prisoner
5. Presence of any active malignancy (other than non-melanoma
skin cancer) that required treatment within the last two years
6. Any other irreversible disease or condition for which six-month
mortality is estimated to be greater than 50%
7. Moderate to severe liver failure (Childs-Pugh Score > 12)
8. Severe chronic respiratory disease with a PaCO2 > 50 mmHg
or the use of home oxygen
9. Patient, surrogate, or physician not committed to full support
(exception: a patient will not be excluded if he/she would
receive all supportive care except for attempts at resuscitation
from cardiac arrest).
10. Major trauma in the prior five days
11. Lung transplant patient
12. No consent/inability to obtain consent
13. Moribund patient not expected to survive 24 hours
14. WHO Class III or IV pulmonary hypertension [27]
15. Documented deep venous thrombosis or pulmonary
embolism within past three months
16. No arterial line/no intent to place an arterial line
17. No intent/unwillingness to follow lung protective ventilation
strategy or fluid management protocol
18. Currently receiving extracorporeal life support or high-frequency
oscillatory ventilation
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range of 88 to 95% without any increase in
ventilator settings
2. Stable vasopressor use if the patient requires
vasopressors for blood pressure support. The dose
of vasopressor may be able to be increased no
more than:
5 mcg/minute for norepinephrine
50 mcg/minute increase for phenylephrine dose
5 mcg/kg/minute increase for dopamine dose
0.5 mcg/kg/minute increase for epinephrine.
These criteria were designed to reduce noise such that
a harmful effect of MSCs could be more clearly identified.
Cell-based therapy requires coordination with the bone
marrow transplantation facility for investigational product
preparation. Patients in phase 2 will be randomized after
confirmation that the cells can be prepared and delivered
to the ICU within four hours and when patients are likely
to achieve a two-hour stable baseline period.
Treatment groups and randomization
In phase 1, there are three planned cohorts with 3 sub-
jects in each cohort who will receive doses of 1× 10
6
cells/kg, 5 ×10
6 cells/kg, and 10×10
6 cells/kg predicted
body weight in an escalating fashion. In phase 2, subjects
will be randomized in a 2:1 randomization scheme to re-
ceive the maximum tolerable dose of MSCs determined
in phase 1 or Plasma-lyte A placebo. Sixty patients will
be randomized by bone marrow transplant laboratory
personnel using a centralized data management system.
Blinding of the investigational product will be preserved
throughout the study. No treatment group information
is provided to the investigators or clinicians caring for
the patient except in case of an emergency, and a log of
unblinding events will be maintained. An unaffiliated ex-
ternal medical monitor will work with investigators to
determine when and if unblinding should occur.
Study procedures
All study procedures except for pre-screening occur
after informed consent is obtained from a subject or his/
her surrogate. The study flow is summarized in Figure 1.
In phase 1, following informed consent, the bone marrow
transplantation laboratory at the clinical site is notified
that there is an eligible patient and of the approximate
time of the infusion (based on the planned start of the
baseline infusion period). The bone marrow transplant-
ation laboratory then determines the dose of cells to be
administered based on the patient’sp r e d i c t e db o d yw e i g h t
[4]. After initiation of the baseline stability period, the
bone marrow transplantation laboratory thaws and
washes the human MSCs. The cells are then resuspended
in Plasma-lyte A for the study infusion. The final volume
of the study infusion is 100 mls (of either human MSCs or
placebo Plasma-lyte A).
Because critically ill patients often experience minute-
to-minute changes in vital signs, we have mandated that
the MSCs infusion can only begin after a two-hour
period of stable baseline has been documented. Stable
baseline is defined as: transcutaneous oxygen saturation
in the target range of 88 to 95% without any increase in
ventilator settings and stable vasopressor use if the patient
requires vasopressors for blood pressure support. The
dose of vasopressor may be able to be increased a small
amount during this two-hour period, predefined as in
Table 2. If the patient is on vasopressin, investigators will
be asked not to titrate the vasopressin dose during this
two-hour period. In addition, patients are considered
clinically unstable and not eligible to receive MSCs if they
require an FiO2≥0.9, PEEP ≥15 cm H2O, 3 vasopressors
or the use of>0.1 mcg/kg/minute epinephrine for blood
pressure support. Finally, given the recent interest in
prone positioning, we amended the protocol to state expli-
citly that patients must be in the supine position for the
baseline period, cell infusion and post-infusion monitoring
period to reduce the likelihood of respiratory or hemody-
namic instability related to changes in position.
The investigational product can be infused via periph-
eral or central venous access, though if administered
through a peripheral intravenous access, it should be at
least 20-gauge, and ideally 18-gauge. The protocol recom-
mends against co-administration with a medication or
dextrose-containing solution. The cells are administered
through a standard blood filter tubing set with a 170 to
260 micron filter via gravity; droplet count is used to con-
trol the infusion rate. The rationale for this approach is
that several of the laboratories in our group do not rou-
tinely infuse cell-based therapies via an infusion pump,
which has the potential to cause mechanical disruption of
the cells. The investigational product is infused over ap-
proximately 60 minutes. Ventilator management, includ-
ing weaning, follows the modified ARDS Network lower
tidal volume (6 ml/kg predicted body weight) protocol
because using this ventilator management protocol will
standardize the application of PEEP, which is a component
of one of the respiratory efficacy endpoints, the LIS,
thus reducing the potential for bias. Patients are man-
aged with a conservative fluid management protocol.
The fluid management strategy is held for four hours
prior to and six hours after the MSC infusion to reduce
the likelihood that the fluid management strategy im-
pacts hemodynamic stability around the time of the study
intervention.
Blood and urine samples are obtained at multiple time
points before and after the infusion of investigational
product for biomarker measurements, which include
measurements of epithelial injury, inflammation and of
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bronchoalveolar lavage is planned.
For clinical endpoint and safety measurements, if not
obtained as part of clinical care, patients will undergo an
arterial blood gas measurement and chest radiograph on
day 3 (after administration of the investigational product)
since these are secondary endpoints of the phase 2 trial.
Serum creatinine, total bilirubin and alanine aminotrans-
ferase (ALT) are measured on days 3, 7 and 14 (after ad-
ministration of the investigational product) for safety
monitoring if subjects are still hospitalized. Vital status as
well as the need for dialysis will be assessed at 6 and
12 months after study enrollment via a telephone visit and
in-person visit, respectively. Data on subsequent hospi-
talizations will also be collected. At the in-person visit, a
limited physical exam will be conducted.
Quality control
At the time of cell thaw at each clinical site, samples of
the MSCs are taken by the bone marrow transplantation
laboratory for standardized quantitation of cell viability
and for cell sterility assays. Protocols for cell thawing
and washing as well as infusion were developed at the
coordinating center at the University of California, San
Francisco. These include the use of standard calculations
to determine the appropriate dose of MSCs, standard
protocols for cell thaw, transfer and washing, as well as
protocols to ensure that the infusion is delivered over
the protocol-specified timeframe. These standard operat-
ing procedures were adapted at each clinical site and
reviewed and approved by the Coordinating Center prior
to initiation of study enrollment at each site. Given the
cell-based nature of this therapy and concerns about cell
viability with variability in cell handling, this is a critical
step for the implementation of a cell-based therapy study.
Study variables
Detailed demographic data and medical history, including
smoking and alcohol history and baseline renal function,
as well as data for baseline severity of illness, includ-
ing the Acute Physiology, Age, Chronic Health Evaluation
(APACHE) III [28], SOFA [24], and Brussels organ failure
scores [29] will be recorded. During the stable baseline, in-
fusion and post-infusion monitoring periods, physiological
variables including heart rate, blood pressure, urine output
and use of vasopressors, along with respiratory variables
including ventilator settings and oxygen saturation will be
recorded on a frequent and pre-specified basis. After
the investigational product infusion, daily data will be
collected for severity of illness scores as well as for lung
injury score at days 1, 2, 3, 7, 14, and 28. In addition to
clinical data, biospecimens are collected, immediately
Screened
Excluded
Enrolled: 
PaO2/FiO2 < 200 on PEEP   8 AND
Likely to achieve stable baseline for 2 hours
Infused
Monitoring 
for AE
Reporting to 
DSMB
each dosing cohort
- After each dosing 
cohort of 3 patients 
complete
Cell preparation 
by BMT laboratory
After 2 hours of 
stable baseline achieved
Figure 1 Flow diagram for the phase 1 component of the START trial. Abbreviations are as follows: acute respiratory distress syndrome,
ARDS; adverse event, AE; bone marrow transplantation, BMT; Data Safety Monitoring Board, DSMB; positive end-expiratory pressure, PEEP.
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measurements. All samples will be shipped to the coordin-
ating center at the University of California, San Francisco.
Sample size
The planned sample size for the phase 1 study is 9 pa-
tients (3 cohorts of 3 patients who will receive escalating
doses of MSCs using a traditional phase 1 design [30].
The sample size for the phase 2 portion of the trial will
be 60 patients randomized 2:1 to receive MSCs or placebo.
The sample size was originally based on the proposed pri-
mary endpoint of change in four-point acute lung injury
score from baseline to day 7 of the study. We selected this
endpoint because at least two randomized clinical trials
have shown that an improvement in the four-point lung
injury score correlates with clinical benefits, including
mortality and ventilator-free days, the two most widely ac-
cepted clinical endpoints for phase 3 trials in ARDS [5,20].
With 20 patients in the placebo arm and 40 patients in the
MSC arm, we would have 87% power to detect a 0.6 point
difference in the lung injury score between the 2 treatment
arms, assuming a standard deviation in lung injury score
of 1.0, and a correlation of 0.7 between measurements.
This effect size is similar to what was reported by Meduri
and colleagues for a methyprednisolone infusion for early
ARDS (0.54 point change in lung injury score over 7 days,
P=0.004) and smaller than that reported for higher dose
methylprednisolone for late ARDS (1.3 point change,
P =0.001) [31,32]. However, during the final design of
t h ep h a s e2t r i a l ,w er e v i s e dt h ep r i m a r ye n d p o i n to f
the study to focus on safety, rather than efficacy. At the
current sample size, as detailed in the Analysis plan, the
trial will allow for estimates of the proportion of subjects
who experience an adverse event in the MSC and pla-
cebo-treated arms as well as the standard effect size of
MSCs for clinical outcomes. This clinical and biological
data will aid in sample size projections for subsequent
phase 2b/3 clinical trials.
Results and discussion
Analysis plan
For the phase 1 study, the analysis will be descriptive.
Specifically, we will describe the incidence of serious
adverse events, including death, as well as the incidence of
pre-specified infusion associated events and non-serious
adverse events felt to be related to the study infusion.
For the phase 2 study, we will describe the incidence
of serious adverse events, including death, as well as the
incidence of pre-specified infusion associated events and
non-serious adverse events felt to be related to the study
infusion in the MSC-treated versus placebo arms. Ana-
lysis of the primary safety endpoint will be focused on
characterizing the adverse event proportion in each
treatment arm, whereas the secondary efficacy endpoints
will be used for the design of larger efficacy studies. We
will compare the incidence of adverse events by treat-
ment cohort using the Pearson’s chi-square test or the
Student’s t-test. The per-treatment arm sample sizes
were generated based on an assumption of a 28-day ad-
verse event proportion of 30%. In this setting, the 95% CI
length for a binomial proportion is 24%, ranging from
19% to 43%.
Because the phase 2 trial is focused on safety and has
limited power for physiological endpoints, the analysis
will be based on an approach using standardized effect
sizes (the difference in mean values between treatment
and control divided by the standard deviation). This ap-
proach allows us to evaluate the efficacy of MSCs in a
small sample size by comparing the effect size observed
in our phase 2 trial to effects observed in larger trials of
therapies known to be efficacious. In the case of ARDS,
the comparison trials would be those of lower tidal
volume ventilation [4] and fluid conservative therapy [5].
We will use the incidence of adverse events along with
an overall assessment of the potential efficacy of MSCs
using the pre-specified respiratory, clinical and biological
endpoints to make a determination as to whether or not
a larger phase 2b study is safe and warranted.
Data safety and monitoring
As described in the prior sections, unique features of
this clinical trial include the requirement for a two-hour
baseline stability period prior to investigational product
infusion and the definition of pre-specified infusion asso-
ciated events. These are intended to ensure subject safety
despite underlying critical illness and to minimize the
potential for instability due to the severity of underlying
illness rather than the investigational product.
The data safety and monitoring plan for this phase 1/2
trial includes a formal Data Safety Monitoring Board
(DSMB) that has been reviewed and approved by the
IRB at the University of California, San Francisco and the
National Heart, Lung and Blood Institute. The DSMB
includes critical care physicians with phase 1/2 trial ex-
perience and a biostatistician. The DSMB is required to
provide recommendations about starting, continuing, and
stopping the study. In addition, the DSMB is asked to
make recommendations, as appropriate, to the NHLBI
about: benefit/risk ratio of procedures and participant bur-
den; selection, recruitment, and retention of participants;
adherence to protocol requirements; completeness, qual-
ity, and analysis of measurements; amendments to the
study protocol and consent forms; performance of individ-
ual centers and core labs; participant safety; notification of
and referral for adverse events.
Since this is a phase 1/2 clinical trial focused on safety
and since the patient population is critically ill and at
high risk for complications related to their underlying
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http://www.annalsofintensivecare.com/content/4/1/22severity of illness, we have also appointed a designated
external medical monitor and constituted a scientific
review committee, chaired by the external medical moni-
tor. In phase 1, the scientific review committee plays a
critical role in evaluation of each patient in each dosing
cohort to ensure patient safety. Specifically, in phase 1,
the first subject in each cohort who receives the MSC
infusion is observed for seven days prior to enrollment
of the remaining subjects in that cohort. A report of
clinical data and adverse events from the first subject in
the cohort is reviewed by the scientific review commit-
tee. If the patient meets stopping criteria (pre-specified
infusion associated event or serious adverse event in-
cluding death within seven days) or there is concern on
the part of the scientific review committee, enrollment
will be suspended pending review by the DSMB. If stop-
ping criteria are not met, and there are no safety con-
cerns, the next two subjects in that cohort may be
enrolled. The second and third subjects in the cohort
may be enrolled concurrently; however if the second
subject experiences a pre-specified clinically important
event or unexpected serious adverse event, including
death, prior to enrollment/dosing of the third study
subject, enrollment/dosing will be suspended pending
review by the DSMB. After completion of enrollment of
each study cohort and seven days of follow-up for all
three individuals in the cohort, an aggregate report of
clinical data and all adverse events will be reviewed by
the scientific review committee and DSMB for each
cohort. After completion of the phase 1 study (28 days
of follow-up for all study subjects), the scientific review
committee will review the data and propose a cell prod-
uct dose for the phase 2 study. This recommendation
will be submitted to the DSMB for approval prior to
initiating the phase 2 study.
In phase 2, the external medical monitor will assist the
study with adjudication of severe adverse events on a
case-by-case basis.
Conclusions
Phase 1/2 trials of a cell-based therapy in critically ill
subjects pose unique design challenges, including the
need for clearly defined criteria for clinical stability prior
to study treatment and the need to define infusion asso-
ciated adverse events in order to try to separate medical
events related to the patient’s overall condition from
events that could be related to the cell-based therapy.
The need to define ‘baseline stability’ poses additional
challenges related to the need to coordinate cell admin-
istration with the bone marrow transplantation labora-
tory. We describe here some of our proposed solutions
to these issues, which should be applicable to both cell-
based therapy trials for other diseases, as well as most
other early phase trials based in the ICU.
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